STAT3 and metabolic dysfunction-associated steatotic liver disease: 2.2. mRNA Sequencing Indicated That Resmetirom Might Improve NAFLD/NASH by Influencing the Activation of Toll-like Receptor and Jak-STAT3 Signaling Pathways